Speaker illustration

Doctor Martin Unverdorben

Daiichi Sankyo, Inc., Basking Ridge, NJ (United States of America)

One-year effectiveness and safety outcomes of edoxaban treatment in Chinese patients with atrial fibrillation: First snapshot of more than 4,800 patients from the ETNA-AF-China study

Event: EHRA 2024

Topic: Stroke in Atrial Fibrillation

Session: Poster session on devices, others


Periprocedural management of patients on edoxaban undergoing pacemaker and cardiac monitoring device implantation - a sub-analysis of the EMIT-AF/VTE study

Event: EHRA 2021

Topic: Oral Anticoagulation

Session: ePoster session


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb